Teva Pharmaceutical Industries (NYSE:TEVA) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 3.6% this past week
Pfizer, Teva Pharmaceuticals, Silverstein Properties, Azrieli honored - The Jerusalem Post
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' | Markets Insider
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters